Condition: Drug Allergy
Intervention: Drug: Omalizumab
Sponsors: Dana-Farber Cancer Institute; Novartis Pharmaceuticals
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Drug Allergy
Intervention: Drug: Omalizumab
Sponsors: Dana-Farber Cancer Institute; Novartis Pharmaceuticals
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Conditions: Prednisone Dependent Asthma; Eosinophilic Bronchitis
Interventions: Biological: Omalizumab (Xolair); Drug: Placebo
Sponsors: McMaster University; Parameswaran Nair; Novartis
Not yet recruiting – verified January 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Severe IgE-mediated Asthma
Interventions: Drug: Omalizumab; Drug: Budesonide; Drug: Formoterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified July 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
The effect of omalizumab on ventilation and perfusion in adults with allergic asthma.
Am J Nucl Med Mol Imaging. 2013;3(4):350-60
Authors: Kelmenson DA, Kelly VJ, Winkler T, Kone MT, Musch G, Melo MF, Venegas JG, Harris RS
Abstract
Omalizumab promotes clinical improvement in patients with allergic asthma, but its effect on pulmonary function is unclear. One possibility is that omalizumab improves asthma symptoms through effects on the regional distributions of ventilation, perfusion, and ventilation/perfusion matching, metrics which can be assessed with Nitrogen-13-saline Position Emission Tomography (PET). Four adults with moderate to severe uncontrolled allergic asthma underwent symptom assessment, spirometry and functional pulmonary imaging with Nitrogen-13-saline PET before and after 4-5 months of treatment with omalizumab. PET imaging was used to determine ventilation/perfusion ratios, the heterogeneity (coefficient of variation, COV) of ventilation and perfusion, and lung regions with ventilation defects. There were no significant changes in spirometry values after omalizumab treatment, but there was a trend towards an improvement in symptom scores. There was little change in the matching of ventilation and perfusion. The COV of perfusion was similar before and after omalizumab treatment. The COV of ventilation was also similar before (0.57 (0.28)) and after (0.66 (0.13)) treatment, and it was similar to previously published values for healthy subjects. There was a non-significant trend towards an increase in the extent of ventilation defects after omalizumab treatment, from 5 (15)% to 12.8 (14.7)%. Treatment of moderate to severe uncontrolled allergic asthma with omalizumab did not result in a significant improvement in ventilation and perfusion metrics assessed with functional PET imaging. The normal COV of ventilation which was unaffected by treatment supports the hypothesis that omalizumab exerts its clinical effect on lung function during allergen exposure rather than in between exacerbations.
PMID: 23901360 [PubMed]
View full post on pubmed: asthma
Asthma drug omalizumab cuts treatment needs
Nursing Times Severe persistent allergic asthma sufferers treated with omalizumab have been shown to use far fewer NHS resources than those treated with other drugs. The drug, marketed as Xolair, has also been shown to significantly improve users' health-related … Novartis study shows cost-effectiveness benefits of Xolair |
View full post on asthma – Google News
Omalizumab effective in treating inadequately controlled allergic asthma
HealthCanal.com HOUSTON — Patients with severe allergic asthma that is inadequately controlled with the standard of care had improved symptoms and decreased flare-ups with injections of an antibody drug called omalizumab, according to experts at Baylor College of … |
View full post on asthma – Google News
Omalizumab effective in treating inadequately controlled allergic asthma
BCM News HOUSTON — (May 5, 2011) — Patients with severe allergic asthma that is inadequately controlled with the standard of care had improved symptoms and decreased flare-ups with injections of an antibody drug called omalizumab, according to experts at … Adding Omalizumab May Improve Uncontrolled Asthma |
View full post on asthma – Google News
MedIndia |
Omalizumab could provide asthma relief for kids
Examiner.com A new study just published online in the New England Journal of Medicine may offer hope to inner-city kids with asthma. Researchers studied inner-city children, adolescents, and young adults with persistent asthma for 60 weeks in a randomized, … Xolair Reduces Seasonal Asthma Attacks for Inner City Kids: Study Hope for children with allergic asthma Study Finds Adult Asthma Drug Dramatically Reduces Seasonal Attacks in Kids |
View full post on asthma – Google News
LiveScience.com |
Omalizumab improves asthma control in inner-city children
Clinical Advisor Adding omalizumab to guidelines-directed asthma therapy reduces seasonal exacerbations and the need for controller medication among inner-city children, regardless of asthma severity, results from the Inner City Anti-IgE Therapy for Asthma (ICATA) … Omalizumab 'cuts seasonal asthma attacks in youth' Drug may relieve kids' asthma in the fall Asthma Drug Cuts Seasonal Flares for Inner-City Kids |
View full post on asthma – Google News
LiveScience.com |
Omalizumab 'cuts seasonal asthma attacks in youth'
DailyIndia.com London, Mar 17: A clinical trial has found that the drug omalizumab, sold under the brand name Xolair, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among inner-city children and youth. … Drug may relieve kids' asthma in the fall Xolair Relieves Kids' Seasonal Asthma Attacks: Study Asthma Drug Cuts Seasonal Flares for Inner-City Kids |
View full post on asthma – Google News